Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of CAR-T Cells in Relapsed/Refractory Hematological Malignancies
NCT05528887Phase 1Recruiting
- Sponsor
- The Affiliated People’s Hospital of Ningbo University
- Start
- Sep 2021
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in hematologic malignancy, lymphoma, multiple myeloma (MM) and 1 more, sponsored by The Affiliated People’s Hospital of Ningbo University. Primary endpoints: Treatment-Emergent Adverse Events at 4 weeks, Treatment-Related Adverse Events at 4 weeks and 1 more. Started Sep 2021; status: recruiting.
02
Conditions
hematologic malignancylymphomamultiple myeloma (MM)leukemia
Beyond the preview
Go deeper on NCT05528887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05528887.